Parsons James T. - 01 Jun 2025 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role
Director
Signature
/s/ Scott Kellen, attorney-in-fact
Issuer symbol
DMAC
Transactions as of
01 Jun 2025
Net transactions value
$0
Form type
4
Filing time
03 Jun 2025, 16:17:39 UTC
Previous filing
03 Jan 2025
Next filing
25 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Parsons James T. Director 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS /s/ Scott Kellen, attorney-in-fact 03 Jun 2025 0001759855

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding DMAC Voting Common Shares, no par value per share 75,854 01 Jun 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DMAC Stock Option (right to buy) Award $0 +40,739 $0.000000 40,739 01 Jun 2025 Common Shares 40,739 $4.11 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 69,754 shares issuable upon vesting and settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, as amended from time to time.
F2 Vests in four nearly equal quarterly installments over one year.